Affimed enrols first Hodgkin's lymphoma patients
This article was originally published in Scrip
Executive Summary
Affimed Therapeutics has announced that it has treated the first Hodgkin’s lymphoma patients with its AFM13 TandAb antibody in a Phase I clinical study. AFM13 is a bispecific, tetravalent human antibody against CD30 and CD16, has Orphan Drug designation for the indication in both Europe and the US.